| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | M-ABC2; MTABC2; EST20237 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ABCB10 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FRK抗体的示例参考文献(注：文献为示例性内容，建议通过学术数据库验证真实文献)：
---
1. **文献名称**: *"Structural and Functional Characterization of FRK Kinase and Its Antibody-Based Detection in Cancer Cells"*
**作者**: Smith A, et al.
**摘要**: 本研究解析了FRK激酶的晶体结构，并开发了一种高特异性单克隆抗体，用于检测多种癌细胞系中FRK的异常表达。实验表明该抗体在Western blot和免疫组化中具有高灵敏度，为癌症诊断提供了新工具。
2. **文献名称**: *"FRK Antibody as a Potential Therapeutic Agent in Breast Cancer: Targeting Tyrosine Kinase Signaling"*
**作者**: Chen L, et al.
**摘要**: 通过体外和体内实验，验证了抗FRK抗体通过抑制酪氨酸激酶活性阻断乳腺癌细胞增殖和迁移的机制。研究提出FRK抗体可能成为靶向治疗的候选药物。
3. **文献名称**: *"Development of a FRK-Specific Polyclonal Antibody for Neurological Disease Research"*
**作者**: Gupta R, et al.
**摘要**: 该文献报道了一种兔源多克隆抗体的制备方法，用于检测脑组织中FRK的表达变化。研究显示，FRK在阿尔茨海默病模型中的表达水平显著升高，提示其与神经退行性疾病的相关性。
4. **文献名称**: *"FRK Antibody Cross-Reactivity Analysis: Implications for Precision Medicine"*
**作者**: Park J, et al.
**摘要**: 系统评估了商用FRK抗体的交叉反应性，发现部分抗体与其他激酶家族成员(如Src)存在非特异性结合。研究呼吁标准化抗体验证流程以提高实验可重复性。
---
建议通过PubMed、Google Scholar等平台检索最新文献，使用关键词“FRK antibody”、“FRK kinase”或“FRK function”获取更准确的信息。
FRK (Fyn-related kinase), also known as PTK5. is a non-receptor tyrosine kinase belonging to the Src family kinase (SFK) group. Discovered in the 1990s, FRK is distinguished by its unique structure, lacking the N-terminal lipid modification site common in other SFKs, which restricts its localization to the cytoplasm. It plays a regulatory role in cell proliferation, differentiation, and apoptosis, primarily through modulating signaling pathways like Ras/MAPK and PI3K/AKT. FRK is notably implicated in cancer biology, acting as a tumor suppressor in certain contexts. For instance, it downregulates oncogenic signaling by phosphorylating and inhibiting receptors such as EGFR and HER2. and its expression is often reduced or lost in breast, pancreatic, and liver cancers due to epigenetic silencing.
FRK-specific antibodies are essential tools for studying its expression, activation, and interactions in disease models. These antibodies enable detection via techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding research into FRK's dual roles—both suppressing and, paradoxically, promoting tumorigenesis in specific cancers. Commercial FRK antibodies are typically validated for specificity against its unique SH2 and SH3 domains. Challenges remain in understanding context-dependent FRK behavior, driving ongoing research to explore its therapeutic potential as a biomarker or target in precision oncology.
×
